title: Development of Myasthenia gravis due to treatment of chronic hepatitis C with a combination of interferon-alpha and ribavirin.
authors.forename: M
authors.initials: M
authors.lastname: Bektas
authors.forename: H
authors.initials: H
authors.lastname: Bektas
authors.forename: D
authors.initials: D
authors.lastname: Gören
authors.forename: M
authors.initials: M
authors.lastname: Altan
authors.forename: H
authors.initials: H
authors.lastname: Cetinkaya
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects*; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000139:chemically induced* / Q000175:diagnosis; D012254:Ribavirin / Q000009:adverse effects*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin